Clarity Pharmaceuticals Secures U.S. Manufacturing Deal for Prostate Cancer Imaging Agent

Event summary

  • Clarity Pharmaceuticals signed a commercial manufacturing agreement with Nucleus RadioPharma for 64Cu-SAR-bisPSMA, a next-generation prostate cancer imaging agent.
  • The deal covers production at Nucleus's Rochester, Minnesota facility (50,000 doses/year) and future Spring House, Pennsylvania site (600,000 doses/year starting 2028).
  • This expands Clarity's existing manufacturing network, which includes partnerships with SpectronRx, Nusano, and Theragenics.
  • The agreement supports anticipated commercial launch following Phase III trials (AMPLIFY and CLARIFY) and FDA approval.
  • 64Cu-SAR-bisPSMA aims to detect smaller prostate cancer lesions than current PSMA PET standards.

The big picture

This agreement positions Clarity to compete in the growing radiopharmaceutical market, particularly for prostate cancer diagnostics. The deal reflects the industry trend toward specialized manufacturing partnerships to support complex therapeutic production. With multiple facilities covering key U.S. regions, Clarity aims to establish a dominant position in targeted cancer imaging before potential competitors scale similar capabilities.

What we're watching

Regulatory Approval
Whether 64Cu-SAR-bisPSMA will secure FDA approval following Phase III trials, enabling commercial launch.
Manufacturing Scale
The pace at which Clarity can expand its manufacturing network to meet projected demand.
Market Adoption
How quickly 64Cu-SAR-bisPSMA gains traction among clinicians and patients as a superior diagnostic tool.

Related topics

Oncology